Core Insights - Prenetics Global Limited reported a strong financial performance for Q1 2025, with revenue increasing by 336.5% year-over-year to $14.4 million, excluding ACT Genomics [3][7] - The company raised its full-year revenue outlook from $73 - $85 million to $80 - $100 million, reflecting accelerating momentum across its business units [4][13] - Prenetics has a robust cash position of $78 million, allowing for continued innovation and strategic initiatives, including a focus on cryptocurrency and Bitcoin adoption [6][12] Financial Highlights - Revenue from continuing operations was $17.3 million in Q1 2025, a 169.9% increase compared to Q1 2024 [7] - Gross profit from continuing operations reached $7.3 million, up 94.1% year-over-year [7] - Adjusted EBITDA loss from continuing operations was $(6.5) million, an increase of 59.4% compared to the previous year [7] Business Updates - The IM8 brand contributed $5.7 million in revenue for Q1 2025, with expectations of approximately $8.5 million in Q2, representing a 50% quarter-over-quarter increase [4][13] - IM8 has over 55,000 customers and has delivered more than 4.9 million servings of its flagship product [11] - The strategic review of ACT Genomics is nearing conclusion, with an announcement regarding ownership stake expected soon [5] Strategic Initiatives - The company is actively pursuing innovative treasury management approaches, including discussions on digital asset opportunities and Bitcoin adoption [6][12] - Prenetics aims to leverage its strong cash position to enhance its competitive positioning in the health tech sector through strategic crypto initiatives [6][12]